Israel Englander Allakos Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Allakos Inc. stock. As of the latest transaction made, Millennium Management LLC holds 183,562 shares of ALLK stock, worth $60,575. This represents 0.0% of its overall portfolio holdings.

Number of Shares

183,562

Previous 543,784 66.24%

Holding current value

$60,575

Previous $657,000 93.61%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.23 - $1.24 $82,851 - $446,675	-360,222 Reduced 66.24%	183,562 $42,000
Q4 2024 Feb 14, 2025	SELL	$0.62 - $1.5 $284,806 - $689,047	-459,365 Reduced 45.79%	543,784 $657,000
Q3 2024 Nov 14, 2024	SELL	$0.54 - $0.92 $1.31 Million - $2.23 Million	-2,419,946 Reduced 70.69%	1,003,149 $652,000
Q2 2024 Aug 14, 2024	BUY	$1.0 - $1.45 $169,675 - $246,028	169,675 Added 5.22%	3,423,095 $3.42 Million
Q1 2024 May 15, 2024	BUY	$1.02 - $3.23 $2.34 Million - $7.4 Million	2,291,706 Added 238.29%	3,253,420 $4.1 Million
Q4 2023 Feb 14, 2024	SELL	$1.72 - $3.18 $476,421 - $880,825	-276,989 Reduced 22.36%	961,714 $2.63 Million
Q2 2023 Aug 14, 2023	BUY	$3.6 - $5.25 $1.24 Million - $1.8 Million	343,338 Added 38.35%	1,238,703 $5.4 Million
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $261,246 - $502,443	60,755 Added 7.28%	895,365 $3.98 Million
Q4 2022 Feb 14, 2023	SELL	$5.66 - $8.42 $3.8 Million - $5.66 Million	-672,177 Reduced 44.61%	834,610 $7.03 Million
Q3 2022 Nov 14, 2022	SELL	$3.02 - $6.12 $1.16 Million - $2.34 Million	-382,496 Reduced 20.25%	1,506,787 $9.22 Million
Q2 2022 Aug 15, 2022	SELL	$2.6 - $6.14 $825,988 - $1.95 Million	-317,688 Reduced 14.39%	1,889,283 $5.91 Million
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $1.55 Million - $2.98 Million	304,186 Added 15.99%	2,206,971 $12.6 Million
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $16.2 Million - $213 Million	1,899,899 Added 65831.57%	1,902,785 $18.6 Million
Q3 2021 Nov 15, 2021	SELL	$76.53 - $110.43 $5.34 Million - $7.7 Million	-69,760 Reduced 96.03%	2,886 $306,000
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $4.41 Million - $5.9 Million	51,668 Added 246.3%	72,646 $6.2 Million
Q1 2021 May 17, 2021	BUY	$109.73 - $153.66 $2.3 Million - $3.22 Million	20,978 New	20,978 $2.41 Million
Q2 2020 Aug 14, 2020	SELL	$44.04 - $80.69 $1.83 Million - $3.35 Million	-41,555 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$44.49 - $93.39 $153,712 - $322,662	-3,455 Reduced 7.68%	41,555 $1.85 Million
Q4 2019 Feb 14, 2020	SELL	$66.49 - $137.73 $1.14 Million - $2.35 Million	-17,094 Reduced 27.52%	45,010 $4.29 Million
Q3 2019 Nov 14, 2019	BUY	$31.0 - $89.73 $1.62 Million - $4.68 Million	52,128 Added 522.53%	62,104 $4.88 Million
Q2 2019 Aug 15, 2019	BUY	$36.0 - $44.73 $359,136 - $446,226	9,976 New	9,976 $432,000
Q1 2019 May 14, 2019	SELL	$33.79 - $51.99 $261,804 - $402,818	-7,748 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$31.59 - $62.65 $53,102 - $105,314	-1,681 Reduced 17.83%	7,748 $405,000
Q3 2018 Nov 14, 2018	BUY	$31.25 - $47.64 $294,656 - $449,197	9,429 New	9,429 $424,000

Others Institutions Holding ALLK

# of Institutions

Shares Held

61M

Call Options Held

71.5K

Put Options Held

19.8K

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $28M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account